Published in Urology on January 01, 2004
A review of the use of somatostatin analogs in oncology. Onco Targets Ther (2013) 0.83
Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer. Front Endocrinol (Lausanne) (2013) 0.80
Alopecia with endocrine therapies in patients with cancer. Oncologist (2013) 0.75
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol (2005) 4.69
Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study. Eur Urol (2007) 2.49
Ureteral obstruction: is the full metallic double-pigtail stent the way to go? Eur Urol (2009) 2.43
The role of adiponectin in human vascular physiology. Int J Cardiol (2011) 2.24
Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol (2007) 2.15
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica (2007) 2.10
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica (2006) 1.71
Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension (2011) 1.67
Long-term results of open transvesical prostatectomy from a contemporary series of patients. Urology (2004) 1.59
Percutaneous nephrolithotomy in horseshoe kidneys: factors affecting stone-free rate. J Urol (2011) 1.57
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica (2006) 1.49
Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology (2012) 1.49
The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets (2004) 1.48
Colorectal cancer stem cells. Stem Cells (2012) 1.47
Enucleoresection for the elective treatment of small renal cell carcinoma: can it be the treatment of choice? Onkologie (2007) 1.45
Tamsulosin versus transurethral resection of the prostate: effect on nocturia as a result of benign prostatic hyperplasia. Int J Urol (2011) 1.44
Primary small cell bladder carcinoma: a case report and review of the current literature. Tumori (2007) 1.42
Bladder lithiasis: from open surgery to lithotripsy. Urol Res (2006) 1.39
Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol (2002) 1.35
Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev (2007) 1.31
Circadian rhythm disruption in cancer biology. Mol Med (2012) 1.31
Spontaneous perforation of the ureter: clinical presentation and endourologic management. J Endourol (2008) 1.29
Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate (2009) 1.25
Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab (2010) 1.24
Muscle regeneration: cellular and molecular events. In Vivo (2009) 1.23
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 1.22
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med (2008) 1.16
Modified ileal neobladder for continent urinary diversion: functional results after 9 years of experience. J Urol (2004) 1.16
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol (2007) 1.15
Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence? J Urol (2005) 1.13
Ultrasound-guided percutaneous nephrostomy performed by urologists: 10-year experience. Urology (2006) 1.10
The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo (2007) 1.10
IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med (2009) 1.08
The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res (2006) 1.07
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res (2010) 1.06
Three-dimensional culture system as a model for studying cancer cell invasion capacity and anticancer drug sensitivity. Anticancer Res (2004) 1.04
Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.04
Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol (2008) 1.04
Characterization of the human urine proteome by preparative electrophoresis in combination with 2-DE. Proteomics (2006) 1.03
The kisspeptin (KiSS-1)/GPR54 system in cancer biology. Cancer Treat Rev (2008) 1.03
Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res (2007) 1.01
Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol (2005) 1.01
Penile fractures: immediate surgical approach with a midline ventral incision. BJU Int (2009) 1.00
Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists. Expert Opin Investig Drugs (2003) 1.00
The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res (2009) 0.99
Cytokines in muscle damage. Adv Clin Chem (2012) 0.98
Short- and long-term complications of open radical prostatectomy according to the Clavien classification system. BJU Int (2008) 0.98
Pseudosarcomatous myofibroblastic lesion of the urinary bladder: a rare entity posing a diagnostic challenge and therapeutic dilemma. Diagn Pathol (2008) 0.97
Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care (2013) 0.96
Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer (2011) 0.96
Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res (2004) 0.95
Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). J Steroid Biochem Mol Biol (2008) 0.94
Symptomatic benign prostate hyperplasia: impact on partners' quality of life. Eur Urol (2002) 0.94
Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med (2008) 0.93
Circulating tumor cells in colorectal cancer: detection methods and clinical significance. Anticancer Res (2009) 0.92
Current status of ureteroscopic treatment for urolithiasis. Int J Urol (2009) 0.92
Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis (2004) 0.92
Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res (2005) 0.91
The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig Drugs (2005) 0.91
The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines. Expert Opin Ther Targets (2007) 0.91
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology (2011) 0.91
Familial female and male germ cell cancer. A new syndrome? Gynecol Oncol (2005) 0.90
Inverse association of leptin levels with renal cell carcinoma: results from a case-control study. Hormones (Athens) (2009) 0.90
Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res (2005) 0.89
Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy. Anticancer Res (2004) 0.89
p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo (2005) 0.89
Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma (2002) 0.89
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol (2006) 0.88
Kiss-1/GPR54 protein expression in breast cancer. Anticancer Res (2014) 0.88
Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies. Int J Inflam (2012) 0.88
Human vascular endothelial cells with extended life spans: in vitro cell response, protein expression, and angiogenesis. Angiogenesis (2002) 0.88
Partial vesiculectomy in an infertile man with seminal vesicle cyst, ipsilateral renal agenesis, and cryptorchidism. Urology (2002) 0.88
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. Clin Lymphoma Myeloma Leuk (2011) 0.88
Syndrome of inappropriate antidiuretic hormone secretion in a patient with hormone refractory prostate cancer. Anticancer Res (2003) 0.88
Use of external ureteral catheters and internal double J stents in a modified ileal neobladder for continent diversion: a comparative analysis. Urol Int (2005) 0.87
Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs (2007) 0.87
Molecular pathogenetics of renal cancer. Am J Nephrol (2006) 0.87
Modified S-pouch neobladder vs ileal conduit and a matched control population: a quality-of-life survey. BJU Int (2004) 0.87
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J (2004) 0.86
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma (2004) 0.86
Problems faced by relatives caring for cancer patients at home. Int J Nurs Pract (2009) 0.86
Detection of circulating tumor cells in bladder cancer patients. Cancer Treat Rev (2008) 0.86
IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells. Anticancer Res (2009) 0.86
Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder. Anticancer Res (2006) 0.86
Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer. World J Urol (2003) 0.86
Insulin-like growth factor-1 isoform mRNA expression in women with endometriosis: eutopic endometrium versus endometriotic cyst. Ann N Y Acad Sci (2006) 0.85
Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab Med (2009) 0.85
Detection of the circulating tumor cells in cancer patients. Future Oncol (2010) 0.85
Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate (2004) 0.85